Found: 20
Select item for more details and to access through your institution.
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 299, doi. 10.1007/s10637-018-0564-2
- By:
- Publication type:
- Article
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 315, doi. 10.1007/s10637-017-0536-y
- By:
- Publication type:
- Article
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 288, doi. 10.1007/s10637-017-0555-8
- By:
- Publication type:
- Article
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 278, doi. 10.1007/s10637-017-0553-x
- By:
- Publication type:
- Article
Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 350, doi. 10.1007/s10637-017-0522-4
- By:
- Publication type:
- Article
Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 206, doi. 10.1007/s10637-017-0533-1
- By:
- Publication type:
- Article
Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 195, doi. 10.1007/s10637-017-0529-x
- By:
- Publication type:
- Article
Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 187, doi. 10.1007/s10637-017-0523-3
- By:
- Publication type:
- Article
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 217, doi. 10.1007/s10637-017-0535-z
- By:
- Publication type:
- Article
Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 346, doi. 10.1007/s10637-017-0521-5
- By:
- Publication type:
- Article
Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 171, doi. 10.1007/s10637-017-0518-0
- By:
- Publication type:
- Article
Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF<sup>V600</sup> mutation-positive solid tumors: a phase 1 study.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 259, doi. 10.1007/s10637-017-0502-8
- By:
- Publication type:
- Article
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 332, doi. 10.1007/s10637-017-0507-3
- By:
- Publication type:
- Article
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 240, doi. 10.1007/s10637-017-0498-0
- By:
- Publication type:
- Article
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 323, doi. 10.1007/s10637-017-0503-7
- By:
- Publication type:
- Article
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 340, doi. 10.1007/s10637-017-0516-2
- By:
- Publication type:
- Article
Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 269, doi. 10.1007/s10637-017-0506-4
- By:
- Publication type:
- Article
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 230, doi. 10.1007/s10637-017-0495-3
- By:
- Publication type:
- Article
The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 307, doi. 10.1007/s10637-017-0468-6
- By:
- Publication type:
- Article
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 248, doi. 10.1007/s10637-017-0499-z
- By:
- Publication type:
- Article